<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04577794</url>
  </required_header>
  <id_info>
    <org_study_id>GLPG3970-CL-210</org_study_id>
    <secondary_id>2020-000659-11</secondary_id>
    <nct_id>NCT04577794</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Ulcerative Colitis</brief_title>
  <acronym>SEA TURTLE</acronym>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of GLPG3970, Administered Orally for 6 Weeks in Adult Subjects With Moderately to Severely Active Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galapagos NV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galapagos NV</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the effect of GLPG3970 compared to placebo&#xD;
      on the signs and symptoms of Ulcerative Colitis (UC) in participants with moderately to&#xD;
      severely active UC.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 5, 2020</start_date>
  <completion_date type="Actual">May 31, 2021</completion_date>
  <primary_completion_date type="Actual">May 17, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Total Mayo Clinical Score (MCS) at Week 6</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <description>Mayo score is an instrument designed to measure disease activity of UC. Total Mayo score consists of 4 sub-scores: stool frequency, rectal bleeding, flexible sigmoidoscopy and physician's global assessment, each graded from 0 to 3. These scores are summed to give a total score range of 0 to 12, with higher total scores indicating more severe disease.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-emergent Adverse Events (TEAEs) by Severity</measure>
    <time_frame>Screening up to Follow-up (Week 13)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed Plasma Trough Concentration (Ctrough) of GLPG3970</measure>
    <time_frame>Predose (within 30 minutes prior to dosing) on Days 15, 29 and 43</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>GLPG3970</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive GLPG3970 solution, orally, once daily for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo solution, orally, once daily for 6 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLPG3970</intervention_name>
    <description>GLPG3970 powder and solvent for oral solution to be reconstituted prior to use.</description>
    <arm_group_label>GLPG3970</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo powder and solvent for oral solution to be reconstituted prior to use.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Documented diagnosis of UC of ≥3 months. The criteria for documentation of UC&#xD;
             diagnosis based on endoscopy will be medical record documentation, and/or a&#xD;
             colonoscopy report dated ≥3 months before screening, which shows features consistent&#xD;
             with UC.&#xD;
&#xD;
          2. Treatment-experienced participants with moderately to severely active disease, who&#xD;
             have either previously demonstrated inadequate clinical response, loss of response, or&#xD;
             intolerance to at least 1 course of standard-of-care (SoC) therapy for UC (i.e.&#xD;
             steroids [oral or parenteral, including but not limited to prednisone, prednisolone,&#xD;
             budesonide], 5-aminosalicylate (5- ASA) derivatives [including but not limited to&#xD;
             mesalamine, sulfasalazine], anti-metabolites [including but not limited to&#xD;
             azathioprine, 6 mercaptopurine, methotrexate], anti-tumor necrosis factor (TNF)&#xD;
             agents, anti-integrins, Janus kinase (JAK) inhibitors), as confirmed by the&#xD;
             investigator.&#xD;
&#xD;
          3. Moderately to severely active UC as determined at screening by:&#xD;
&#xD;
               1. Centrally-read endoscopic evidence of disease activity (MCS- endoscopy subscore&#xD;
                  (ES) ≥2 OR ulcerative colitis endoscopic index of severity (UCEIS) ≥4) with a&#xD;
                  minimum disease extent of 15 cm from anal verge; AND&#xD;
&#xD;
               2. MCS stool frequency (SF) subscore ≥1; AND&#xD;
&#xD;
               3. MCS rectal bleeding (RB) subscore ≥1.&#xD;
&#xD;
          4. Participants currently receiving the following SoC therapies for UC are eligible&#xD;
             providing they have been on a stable dose for the designated period of time and are&#xD;
             anticipated to be stable throughout the study:&#xD;
&#xD;
               1. oral corticosteroids (prednisone ≤20 mg/day or equivalent or budesonide ≤3&#xD;
                  mg/day) stable dose for at least 2 weeks prior to first investigational product&#xD;
                  (IP) dosing.&#xD;
&#xD;
               2. oral 5-ASA compounds (mesalamine ≤4 g/day or sulfasalazine ≤4 g/day) stable dose&#xD;
                  for at least 4 weeks prior to first IP dosing.&#xD;
&#xD;
               3. oral thiopurines (azathioprine ≤2.5 mg/kg/day and 6-mercaptopurine 1.5 mg/kg/day)&#xD;
                  stable dose for at least 12 weeks prior to first IP dosing, or methotrexate ≤20&#xD;
                  mg/week, stable dose for at least 12 weeks prior to first IP dosing.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of Crohn's disease, indeterminate colitis, ischemic colitis, fulminant&#xD;
             colitis, or toxic megacolon.&#xD;
&#xD;
          2. Prior surgical intervention for UC (e.g. colectomy, partial colectomy, ileostomy or&#xD;
             colostomy) or likely requirement for surgery for UC, during the study.&#xD;
&#xD;
          3. History or evidence of incompletely resected colonic mucosal dysplasia.&#xD;
&#xD;
          4. Exhibit acute severe UC per the following criteria:&#xD;
&#xD;
               1. bloody diarrhea ≥6/day AND&#xD;
&#xD;
               2. any of the following signs of systemic toxicity: Body temperature (oral or&#xD;
                  tympanic) ≥37.8°C OR Resting pulse (after 5 min seated position) &gt;90 beats per&#xD;
                  min OR hemoglobin &lt;105 g/L, OR erythrocyte sedimentation rate &gt;30 mm/h; OR&#xD;
                  C-reactive protein (CRP) &gt;30 mg/L.&#xD;
&#xD;
          5. Screening stool sample positive for ova and/or parasites, Clostridium difficile toxin,&#xD;
             Escherichia coli, Salmonella species (spp), Shigella spp, Campylobacter spp or&#xD;
             Yersinia spp.&#xD;
&#xD;
          6. Participant testing positive at screening for severe acute respiratory syndrome&#xD;
             coronavirus 2 (SARS-CoV-2) infection as detected by real time polymerase chain&#xD;
             reaction (RT-PCR), participants presenting any signs or symptoms as detected at&#xD;
             baseline following careful physical examination (e.g. cough, fever, headaches,&#xD;
             fatigue, dyspnea, myalgia, anosmia, dysgeusia, anorexia, sore throat, others) or&#xD;
             reporting any signs and symptoms for the preceding 2 weeks, or participants who have&#xD;
             been exposed to individuals with confirmed or suspected diagnosis of SARS-CoV-2 within&#xD;
             2 weeks prior to baseline. In addition, any other locally applicable standard&#xD;
             diagnostic criteria may also apply to rule out SARS-CoV-2 infection.&#xD;
&#xD;
        Note: Other protocol-defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roxana Drake</last_name>
    <role>Study Director</role>
    <affiliation>Galapagos NV</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arensia Exploratory Medicine LLC</name>
      <address>
        <city>Tbilisi</city>
        <zip>0112</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ARENSIA Exploratory Medicine Phase I Unit</name>
      <address>
        <city>Chisinau</city>
        <zip>2025</zip>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne PROMED</name>
      <address>
        <city>Kraków</city>
        <zip>31-513</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endoskopia Sp. z o.o.</name>
      <address>
        <city>Sopot</city>
        <zip>81-756</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ETG Zamosc</name>
      <address>
        <city>Zamość</city>
        <zip>22-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>I.I.Mechnykov Dnipropetrovsk Regional Clinical Hospital</name>
      <address>
        <city>Dnipro</city>
        <zip>49005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ivano-Frankivsk Regional Clinical Hospital</name>
      <address>
        <city>Ivano-Frankivs'k</city>
        <zip>76000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CNE Prof. O.O. Shalimov Kharkiv City Clinical Hospital #2</name>
      <address>
        <city>Kharkiv</city>
        <zip>61037</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHI Kharkiv City Clinical Hospital #13</name>
      <address>
        <city>Kharkiv</city>
        <zip>61124</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Communal Nonprofit Enterprise Kherson City Clinical Hospital n.a. Afanasii and Olga Tropini</name>
      <address>
        <city>Kherson</city>
        <zip>73000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center &quot;Harmoniya Krasy&quot;</name>
      <address>
        <city>Kyiv</city>
        <zip>01135</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Med Center 'Ok!Clinic+' of International Institute of Clinical Trials LLC</name>
      <address>
        <city>Kyiv</city>
        <zip>02091</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M.I. Pyrogov VRCH Dept of Gastroenterology M.I. Pyrogov VNMU</name>
      <address>
        <city>Vinnytsia</city>
        <zip>21018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCH #1 Vinnytsia M.I. Pyrogov NMU Ch of Propaedeutics of IM</name>
      <address>
        <city>Vinnytsia</city>
        <zip>21029</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SRI of Invalid Rehabilitation (EST Complex) of Vinnytsia M.I.Pyrogov NMU MOHU</name>
      <address>
        <city>Vinnytsia</city>
        <zip>21029</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Georgia</country>
    <country>Moldova, Republic of</country>
    <country>Poland</country>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>September 30, 2020</study_first_submitted>
  <study_first_submitted_qc>September 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2020</study_first_posted>
  <last_update_submitted>June 30, 2021</last_update_submitted>
  <last_update_submitted_qc>June 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Colitis</keyword>
  <keyword>Ulcer</keyword>
  <keyword>Moderately active ulcerative colitis</keyword>
  <keyword>Chronic inflammatory bowel disease</keyword>
  <keyword>Inflammatory Bowel Diseases</keyword>
  <keyword>Digestive System Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

